Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Purpose.—Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …

Importance Osimertinib mesylate is used globally to treatEGFR-mutant non–small cell lung
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

The analysis of tumor cells or tumor cell products obtained from blood or other body fluids
(“liquid biopsy”[LB]) provides a broad range of opportunities in the field of oncology. Clinical …

The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …

Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …

Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied
mostly in small cohorts without sufficient follow-up to determine its influence on overall …